In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain

We provide a comparative in vivo examination of the brain network-based distribution of two hallmarks of Alzheimer's disease (AD) pathology in cognitively normal individuals: (1) Tau, detected with a novel positron emission tomography (PET) tracer known as 18F-AV-1451; and (2) amyloid-β, quantified with 11C-PiB PET. We used a high-resolution graph-based approach to investigate local-to-local and local-to-distributed cortical associations between the maps of Tau, amyloid-β, and gray matter intensity. Our study shows that Tau and amyloid-β deposits are associated with distinctive spatial patterns of brain tissue loss. Moreover, Tau and amyloid-β accumulations have strong network interdigitations in heteromodal and associative areas of the cortical mantle, particularly the inferior–lateral temporal lobe. These findings contribute significantly to our understanding of how these two main hallmarks of AD pathology propagate across the elderly human brain. SIGNIFICANCE STATEMENT It has been postulated that Alzheimer's disease (AD) pathology interacts and resides within system-level circuits of the human brain, long before the onset of cognitive symptoms. However, a side-by-side comparison of tissue loss, amyloid-β, and Tau deposition in early stages of the disease has been precluded until the recent advent of Tau tracer-based neuroimaging. In this study, we used Tau positron emission tomography and network analyses to disentangle these pathological relationships. We found that Tau and amyloid-β deposits are associated with distinctive spatial patterns of brain tissue loss. Moreover, we uncovered the network interdigitations of Tau and amyloid-β in the cortical mantle. These findings contribute significantly to our understanding of how two main hallmarks of AD pathology propagate across the elderly human brain.

[1]  Reisa A. Sperling,et al.  Harvard Aging Brain Study: Dataset and accessibility , 2017, NeuroImage.

[2]  Daniel R. Schonhaut,et al.  PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.

[3]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[4]  Keith A. Johnson,et al.  Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.

[5]  C. Jack PART and SNAP , 2014, Acta Neuropathologica.

[6]  Janna H. Neltner,et al.  Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.

[7]  J. Ávila,et al.  The role of extracellular Tau in the spreading of neurofibrillary pathology , 2014, Front. Cell. Neurosci..

[8]  D. Bennett,et al.  A 2-process model for neuropathology of Alzheimer's disease , 2014, Neurobiology of Aging.

[9]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.

[10]  Vincent Doré,et al.  In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Brian J. Bacskai,et al.  Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo , 2013, Proceedings of the National Academy of Sciences.

[12]  Keith A. Johnson,et al.  A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. , 2013, Journal of labelled compounds & radiopharmaceuticals.

[13]  J. Trojanowski,et al.  Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.

[14]  H. Arai,et al.  Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease , 2013, The Journal of Nuclear Medicine.

[15]  Alex Becker,et al.  In vivo characterization of the early states of the amyloid-beta network. , 2013, Brain : a journal of neurology.

[16]  B. Hyman,et al.  Mechanisms of protein seeding in neurodegenerative diseases. , 2013, JAMA neurology.

[17]  Clifford R. Jack,et al.  Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?☆ , 2013, NeuroImage: Clinical.

[18]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. , 2013, Journal of Alzheimer's disease : JAD.

[19]  B. Hyman,et al.  Propagation of Tau Pathology in a Model of Early Alzheimer’s Disease , 2012, Neuron.

[20]  Karen F Berman,et al.  The neurobiology of Alzheimer disease defined by neuroimaging. , 2012, Current opinion in neurology.

[21]  Nick C Fox,et al.  Brain imaging in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[22]  M. Weiner,et al.  A Network Diffusion Model of Disease Progression in Dementia , 2012, Neuron.

[23]  Efstathios D. Gennatas,et al.  Predicting Regional Neurodegeneration from the Healthy Brain Functional Connectome , 2012, Neuron.

[24]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[25]  Andrei G. Vlassenko,et al.  Amyloid‐beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data , 2011, Annals of neurology.

[26]  B. Hyman,et al.  Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.

[27]  M. Weiner,et al.  The dynamics of cortical and hippocampal atrophy in Alzheimer disease. , 2011, Archives of neurology.

[28]  Keith A. Johnson,et al.  Amyloid-β Associated Cortical Thinning in Clinically Normal Elderly , 2011, Annals of neurology.

[29]  Susan M Resnick,et al.  In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. , 2011, Archives of neurology.

[30]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[31]  Marine Fouquet,et al.  Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. , 2010, Brain : a journal of neurology.

[32]  B. Miller,et al.  Neurodegenerative Diseases Target Large-Scale Human Brain Networks , 2009, Neuron.

[33]  Akram Bakkour,et al.  The cortical signature of prodromal AD , 2009, Neurology.

[34]  Keith A. Johnson,et al.  Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease , 2009, The Journal of Neuroscience.

[35]  J. Morris,et al.  The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals , 2008, Cerebral cortex.

[36]  Akram Bakkour,et al.  The cortical signature of prodromal AD Regional thinning predicts mild AD dementia , 2009 .

[37]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[38]  Yvette I. Sheline,et al.  Potential antecedent marker of Alzheimer disease , 2006 .

[39]  Vladimir Batagelj,et al.  Exploratory Social Network Analysis with Pajek: Revised and Expanded Edition for Updated Software , 2018 .

[40]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  David C. Van Essen,et al.  A Population-Average, Landmark- and Surface-based (PALS) atlas of human cerebral cortex , 2005, NeuroImage.

[42]  Benjamin J. Shannon,et al.  Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.

[43]  R. Buckner Memory and Executive Function in Aging and AD Multiple Factors that Cause Decline and Reserve Factors that Compensate , 2004, Neuron.

[44]  M. Mattson Pathways towards and away from Alzheimer's disease , 2004, Nature.

[45]  D. Selkoe,et al.  Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. , 2004, Protein and peptide letters.

[46]  M. Greicius,et al.  Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI , 2004, Proc. Natl. Acad. Sci. USA.

[47]  M. Albert,et al.  Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain , 2004, Neurology.

[48]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[49]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[50]  W. Klunk,et al.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.

[51]  Jean-Claude Baron,et al.  Early diagnosis of alzheimer’s disease: contribution of structural neuroimaging , 2003, NeuroImage.

[52]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[53]  Karl J. Friston,et al.  Voxel-Based Morphometry—The Methods , 2000, NeuroImage.

[54]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[55]  N. Foster,et al.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.

[56]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[57]  P. Scheltens,et al.  Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[58]  C. Jack,et al.  MR‐based hippocampal volumetry in the diagnosis of Alzheimer's disease , 1992, Neurology.

[59]  H. Braak,et al.  Demonstration of Amyloid Deposits and Neurofibrillary Changes in Whole Brain Sections , 1991, Brain pathology.

[60]  G. V. Van Hoesen,et al.  The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.

[61]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[62]  H. Braak,et al.  The presubicular region in Alzheimer's disease: topography of amyloid deposits and neurofibrillary changes , 1989, Brain Research.

[63]  Satoru Kawai,et al.  An Algorithm for Drawing General Undirected Graphs , 1989, Inf. Process. Lett..

[64]  K. Ogomori,et al.  Beta-protein amyloid is widely distributed in the central nervous system of patients with Alzheimer's disease. , 1989, The American journal of pathology.

[65]  T. Powell,et al.  The Neuroanatomy of Alzheimer's Disease , 1989, Reviews in the neurosciences.

[66]  G. V. Van Hoesen,et al.  Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. , 1984, Science.

[67]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[68]  A. Nappi,et al.  Alzheimer ' s Disease : Cell-Specific Pathology Isolates the Hippocampal Formation , 2022 .